This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (45)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Articles for Residents  • Glaucoma  • Alert me on articles by topic

Robert N. Weinreb, MD; Leonard A. Levin, MD, PhD

Arch Ophthalmol. 1999;117:1540-1544.

Treatment of glaucoma continues to be directed at lowering intraocular pressure to decrease the likelihood of disease progression. In the future intraocular pressure reduction might be augmented by other therapeutic approaches. Interest has been increasing in preventing progression of glaucomatous optic neuropathy using approaches based on the premise that glaucoma is a neurodegenerative disease. Neuroprotection of the glaucomatous optic nerve therefore would be an adjuctive therapeutic paradigm for use with conventional intraocular pressure–lowering treatments or by itself.

From the Glaucoma Center and Department of Ophthalmology, University of California, San Diego, La Jolla (Dr Weinreb); and Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison (Dr Levin). Both authors are consultants for several pharmaceutical companies involved with potential neuroprotective drugs. Dr Weinreb has served as a consultant or received research support from companies including Alcon Laboratories Inc, Allergan Inc, Merck & Co Inc, and Pharmacia & Upjohn.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Yucel et al.
Arch Ophthalmol 2006;124:217-225.
ABSTRACT | FULL TEXT  

Evaluation of Inducible Nitric Oxide Synthase in Glaucomatous Optic Neuropathy and Pressure-Induced Optic Nerve Damage
Pang et al.
IOVS 2005;46:1313-1321.
ABSTRACT | FULL TEXT  

Improvement of Spatial Contrast Sensitivity Threshold after Surgical Reduction of Intraocular Pressure in Unilateral High-Tension Glaucoma
Gandolfi et al.
IOVS 2005;46:197-201.
ABSTRACT | FULL TEXT  

An Investigation of the Neuroprotective Effects of Tetracycline Derivatives in Experimental Models of Retinal Cell Death
Baptiste et al.
Mol. Pharmacol. 2004;66:1113-1122.
ABSTRACT | FULL TEXT  

Female reproductive factors and open angle glaucoma: the Blue Mountains Eye Study
Lee et al.
Br. J. Ophthalmol. 2003;87:1324-1328.
ABSTRACT | FULL TEXT  

Optic Nerve Damage in Experimental Mouse Ocular Hypertension
Mabuchi et al.
IOVS 2003;44:4321-4330.
ABSTRACT | FULL TEXT  

Preservation of Aqueous Outflow Facility after Second-Generation FIV Vector-Mediated Expression of Marker Genes in Anterior Segments of Human Eyes
Loewen et al.
IOVS 2002;43:3686-3690.
ABSTRACT | FULL TEXT  

Comparison of the Neuroprotective Effects of Adrenoceptor Drugs in Retinal Cell Culture and Intact Retina
Baptiste et al.
IOVS 2002;43:2666-2676.
ABSTRACT | FULL TEXT  

Discriminating Between Normal and Glaucomatous Eyes Using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph
Zangwill et al.
Arch Ophthalmol 2001;119:985-993.
ABSTRACT | FULL TEXT  

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma
Schori et al.
Proc. Natl. Acad. Sci. USA 2001;98:3398-3403.
ABSTRACT | FULL TEXT